Podcasts about phase iii

Kingfisher Metals reported additional drill and soil results from its 2025 program at the HWY 37 Project in British Columbia's Golden Triangle. Nevada King Gold Corp. reported final results from ten remaining holes of its Phase III drill program at the Silver Park East (SPE) target. Collective Mining announced that drilling is now fully underway at the high-grade, tungsten-rich zones of its **Apollo system**. Great Pacific Gold announced Phase 1 diamond drill results from the Sinivit target at its flagship Wild Dog Project in Papua New Guinea. First Mining Gold announced additional 2025 exploration results from the Miroir target at its Duparquet Gold Project in Quebec's Abitibi region. Foran Mining announced H2 2025 exploration results from the Tesla Zone at its McIlvenna Bay Project in Saskatchewan.This episode of Mining Stock Daily is brought to you by… Integra ResourcesIntegra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.comThe Mining Stock Daily morning briefing is produced by Clear Commodity Network. It is distributed throughout the world through your podcast network of choice, and by our friends at the Junior Mining Network. The information presented should not be considered investment advice. Mining stock daily and its affiliates are not responsible for any loss arising from any investment decision in connection with the material presented herein. Please do your own research or speak with a licensed financial representative before making any investment decisions.

Many of the top stories of 2025 are currently being written. We're on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out over the right to acquire glittery obesity startup Metsera. In the latest development, Pfizer raised its original bid of around $7.27 billion to about $8.1 billion on Monday—only to be usurped again by the indefatigable Novo, which upped its own bid to a cool $10 billion.  Meanwhile, the unprecedented drama in the uppermost ranks of the FDA—another top story of 2025—continues as CDER Director George Tidmarsh exits the agency. Tidmarsh reportedly resigned Sunday after being placed on administrative leave amid an investigation into his “personal conduct” at the agency. On Monday, however, Tidmarsh told Endpoints News that he was “second-guessing” his decision.  Speaking of the FDA, the regulator appears to have done its own 180—on uniQure's investigational gene therapy for Huntington's disease, three-year data from which sent the biotech's stock into the stratosphere just five weeks ago. Despite previous agreements on protocols and statistical analyses, the agency “no longer agrees” that Phase I/II data for AMT-130 are adequate to provide primary evidence for the application, uniQure said, throwing the timeline for the BLA into question.  Another gene therapy player, Sarepta Therapeutics, took a hit this week, as two of its Duchenne muscular dystrophy drugs, Vyondys 53 and Amondys 45, failed a confirmatory trial. Sarepta still plans to file for full approval of the two exon-skipping therapies, however, based on what it called “encouraging trends” in efficacy. Finally, on the genetic medicine front, CBER director Vinay Prasad teased an upcoming paper that will detail the regulator's thinking and a new approach to gene editing approvals.  On top of all that, Q3 earnings continue to roll in, with Pfizer, Eli Lilly, Vertex, Bristol Myers Squibb, AbbVie, and more reporting results.  One more thing: Have you ever wanted to know more about the inner workings of the Biogen-Eisai Alzheimer's partnership? Check out this profile on BioSpace 40 under 40 honoree Neena Bitritto-Garg, Eisai alum and current CEO of Ensho Therapeutics. 

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 31, 2025. In this episode: third quarter dealmaking picks up; Novartis still has M&A firepower even after Avidity acquisition; Hanmi's obesity contender shows Phase III promise; NVIDIA partnership progresses Lilly's AI plans; and Lilly builds gene therapy push with Adverum buy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MQMX2YHSAVHBTJFR4RAEAYNFNQ/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Wir statten mal wieder der Hohen Republik einen Besuch ab und sprechen über eine Reihe, die der Okklusionszone einen Besuch abstattet - Inception! In Nachrichten aus der Okklusionszone gehen alle Hauptreihen von Abenteuer bis zur Marvel-Reihe einen kleinen Umweg. Denn alle werden pausiert, während eine Art Brücke in dieser Reihe erzählt werden soll. Diese Brücke hängt aber nicht wirklich zusammen, sondern jeder baut seinen eigenen Pfeiler. Das sorgt am Ende für unterbrochene Hauptreihen, fehlenden Inhalt dort und eine wenig zusammenhängende Minireihe, auf die wir auch hätten verzichten können. Warum einige Aspekte dennoch Spaß machen, nur eben im Kontext einer Minireihe nicht passen, besprechen Ines, Theo und Tobias deshalb in dieser Ausgabe. Es geht um die Frage, welche der Abzweigungen noch am meisten Spaß macht, warum Ines Angst vor Eriadu hat und wieso einer der größten Pluspunkte aus Echos der Angst nun durch anderen Kontext zu einem Kritikpunkt wird. Außerdem könnt ihr auch was gewinnen, wenn ihr in den spoilerfreien Teil reinhört und hier das Formular ausfüllt. Zeitmarken 00:00:00 - Willkommen zu Nachrichten aus der Okklusionszone 00:01:46 - Erwartungen an die Reihe 00:03:49 - Ersteindruck nach dem Lesen 00:05:50 - Was will die Reihe eigentlich erreichen? 00:07:15 - Warum ist hier eine Zeitmarke? 00:08:12 - Welche Story überzeugt am meisten? 00:10:43 - Notwendig für die Hauptreihen? 00:14:10 - Spoiler ab hier: Immer wieder Eriadu (Heft 1) 00:25:25 - Ruu hat keine Ruh (Heft 2) 00:34:33 - Spurensuche Widerwillen (Heft 3) 00:43:40 - Stil stört Handlung (Heft 4) 00:57:08 - Fazit mit den Ninja Turtles 01:00:40 - Was wir uns gewünscht hätten Blick in die Datenbank Zur Werksübersicht von Nachrichten aus der Okklusionszone (Dispatches from the Occlusion Zone) Die Einzelhefte erschienen ab 4. September 2024 bei Dark Horse Ein englischsprachiger Sammelband erschien am 1. Juli 2025 Der deutsche Sonderband bei Panini erschien am 21. Oktober 2025 Die Rezensionen Theo hat die Reihe als Einzelhefte direkt zum englischsprachigen Release rezensiert. Er fand viele lobende Worte für die Reihe, was aber vor allem an der erfreulich wenigen Exposition im Vergleich zu Schatten von Starlight lag. Tobias hat jetzt zum Release des deutschsprachigen Sonderbands seine Rezension geschrieben. Er konnte dem Anspruch und der Umsetzung der Reihe nicht viel abgewinnen, zumal er im direkten Vergleich noch Echos der Angst im Kopf hatte. Das Werk will Brücke sein, ist aber eher ein zwangsweise zu passierender Fährenhafen, um am anderen Ufer mit den eigentlichen Hauptreihen fortzufahren. Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Unsere Arbeit unterstützen Seit einigen Monaten haben wir nun auch einen Buymeacoffee-Link. Darüber könnt ihr uns einmalig einen gewünschten Geldbetrag zukommen lassen. Damit setzen wir dann Gewinnspiele, Convention-Auftritte (wie demnächst auf der Comic Con in Stuttgart) oder technische Ausstattung für unser Projekt um. Deine Meinung zum Comic Wie hat euch der Sonderband gefallen? Stört euch die Unterbrechung und Auslagerung der Hauptreihen oder ist das genau der Reiz dieses Sonderbandes? Oder fühlt ihr euch auch mehr bei Minireihen wie Echos der Angst zu Hause? Hier geht es zum Gewinnspiel Tragt die Antwort auf die im Podcast gestellte Frage hier unter der Rezension ins Formular ein und gewinnt dank Panini einen von drei Bänden Nachrichten aus der Okklusionszone. Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

Audio roundup of selected biopharma industry content from Scrip over the business week ended October 24, 2025. In this episode we focus on the most significant results presented at the European Society for Medical Oncology meeting in Berlin: Enhertu in early-stage breast cancer; Padcev/Keytruda in bladder cancer; Phase III wins for Pluvicto; Trodelvy and Datroway in breast cancer tussle; and Merck & Co. raises hopes in breast cancer. . Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-EWX3A6U4TBE5NPDYXHIJSWDO3A/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Phase IV of The Change Leader's Roadmap is the Design Phase, where you take your Design Requirements from Phase III to determine the best solution to meet the needs of the future state. This high-level overview is key to ensuring you have a four-quadrant solution that will sustain its value once implemented. Details of the Design Phase are further outlined in Episode 41 of Ask Dr. Change. It covers in-depth the process, structure and requirements of this phase. Review that to embellish this episode so that you ensure you are taking a Conscious Change Leadership approach to Design.Hosted by Ausha. See ausha.co/privacy-policy for more information.

¿Qué hacemos cuando el brazo no se mueve? En este episodio hablamos de ese punto de partida que tanto intimida: el miembro superior completamente pléjico tras un ictus. A partir de la experiencia clínica y la neurofisiología más actual, exploramos cómo comenzar a activar un brazo desde cero. Abordamos estrategias basadas en evidencia como el trabajo en carga en cadena cinética cerrada, la electroestimulación funcional multicanal, el uso de herramientas como el PANAt Laptool, el entrenamiento bilateral y los paradigmas de uso forzado inspirados en Forced-Use Utley/Woll. También repasamos el papel del entrenamiento con soporte de peso, ese enfoque nacido de los laboratorios de Dewald y Ellis que ha cambiado la forma de entender la sinergia flexora. Un episodio para fisioterapeutas y terapeutas ocupacionales que quieren comprender no solo qué hacer, sino por qué hacerlo. Referencias del episodio: 1. Arya, K. N., & Pandian, S. (2014). Interlimb neural coupling: implications for poststroke hemiparesis. Annals of physical and rehabilitation medicine, 57(9-10), 696–713. https://doi.org/10.1016/j.rehab.2014.06.003 (https://pubmed.ncbi.nlm.nih.gov/25262645/). 2. Cauraugh, J. H., & Summers, J. J. (2005). Neural plasticity and bilateral movements: A rehabilitation approach for chronic stroke. Progress in neurobiology, 75(5), 309–320. https://doi.org/10.1016/j.pneurobio.2005.04.001 (https://pubmed.ncbi.nlm.nih.gov/15885874/). 3. Chen, S., Qiu, Y., Bassile, C. C., Lee, A., Chen, R., & Xu, D. (2022). Effectiveness and Success Factors of Bilateral Arm Training After Stroke: A Systematic Review and Meta-Analysis. Frontiers in aging neuroscience, 14, 875794. https://doi.org/10.3389/fnagi.2022.875794 (https://pubmed.ncbi.nlm.nih.gov/35547621/). 4. Ellis, M. D., Carmona, C., Drogos, J., & Dewald, J. P. A. (2018). Progressive Abduction Loading Therapy with Horizontal-Plane Viscous Resistance Targeting Weakness and Flexion Synergy to Treat Upper Limb Function in Chronic Hemiparetic Stroke: A Randomized Clinical Trial. Frontiers in neurology, 9, 71. https://doi.org/10.3389/fneur.2018.00071 (https://pubmed.ncbi.nlm.nih.gov/29515514/) 5. Jang, S. H., & Lee, S. J. (2019). Corticoreticular Tract in the Human Brain: A Mini Review. Frontiers in neurology, 10, 1188. https://doi.org/10.3389/fneur.2019.01188 (https://pubmed.ncbi.nlm.nih.gov/31803130/). 6. Khan, M. A., Fares, H., Ghayvat, H., Brunner, I. C., Puthusserypady, S., Razavi, B., Lansberg, M., Poon, A., & Meador, K. J. (2023). A systematic review on functional electrical stimulation based rehabilitation systems for upper limb post-stroke recovery. Frontiers in neurology, 14, 1272992. https://doi.org/10.3389/fneur.2023.1272992 (https://pubmed.ncbi.nlm.nih.gov/38145118/). 7. Langhorne, P., Wu, O., Rodgers, H., Ashburn, A., & Bernhardt, J. (2017). A Very Early Rehabilitation Trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial. Health technology assessment (Winchester, England), 21(54), 1–120. https://doi.org/10.3310/hta21540 (https://pubmed.ncbi.nlm.nih.gov/28967376/). 8. Michielsen, M., Cornelis, L., Cruycke, L., De Smedt, A., Fobelets, M., Putman, K., Vander Plaetse, M., Verheyden, G., & Meyer, S. (2025). Arm-hand BOOST (AHA-BOOST) therapy to improve recovery of the upper limb after stroke: rationale and description by means of the TIDieR checklist. Frontiers in neurology, 16, 1599762. https://doi.org/10.3389/fneur.2025.1599762 (https://pubmed.ncbi.nlm.nih.gov/41001199/). 9. Schick, T., Kolm, D., Leitner, A., Schober, S., Steinmetz, M., & Fheodoroff, K. (2022). Efficacy of Four-Channel Functional Electrical Stimulation on Moderate Arm Paresis in Subacute Stroke Patients-Results from a Randomized Controlled Trial. Healthcare (Basel, Switzerland), 10(4), 704. https://doi.org/10.3390/healthcare10040704 (https://pubmed.ncbi.nlm.nih.gov/35455881/). 10. Sukal, T. M., Ellis, M. D., & Dewald, J. P. (2007). Shoulder abduction-induced reductions in reaching work area following hemiparetic stroke: neuroscientific implications. Experimental brain research, 183(2), 215–223. https://doi.org/10.1007/s00221-007-1029-6 (https://pubmed.ncbi.nlm.nih.gov/17634933/) 11. Whitall, J., McCombe Waller, S., Silver, K. H., & Macko, R. F. (2000). Repetitive bilateral arm training with rhythmic auditory cueing improves motor function in chronic hemiparetic stroke. Stroke, 31(10), 2390–2395. https://doi.org/10.1161/01.str.31.10.2390 (https://pubmed.ncbi.nlm.nih.gov/11022069/).

The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

Australia has just approved a second amyloid-targeting therapy for patients with incipient Alzheimer's dementia. Lecanemab (Leqembi) now joins donanemab (Kisunla) on the Australian Registry of Therapeutic Goods but the impact of both has been modest in Phase III trials to date. After 18 months of therapy they delay progression of disease, as quantified on neurocognitive tests, by around 5 months on average.  For some, the prolonged independence and dignity will justify the $60,000 to $80,000 a year price tag for the drugs. But for the Pharmaceutical Benefits Advisory Committee “the high burden of [donanemab] treatment on both patients and the health system, combined with the risks and modest clinical impact, makes the drug unsuitable for PBS subsidy”. This burden includes specialist consults, gene screening, multiple MRI and PET brain scans, and delivery of monthly or fortnightly infusions, adding up to another $20,000 in costs. Even before considering these logistical requirements, Australian memory clinics don't have anywhere near the capacity to address the 245,000 new cases of early dementia or mild cognitive impairment every year. Advocates see these disease-modifying therapies as a turning point for dementia research and argue for further investment in the systems infrastructure needed to roll them out. Sceptics argue that the available evidence instead questions the importance of amyloidosis in the Alzheimer's disease cascade.GuestsProfessor Michael Woodward AM FRACP FANZSGM FAAG FAWMA (Austin Health, Melbourne; University of Melbourne) Dr Chrysanth Pulle FRACP (Prince Charles Hospital, Brisbane)  Chapters 13:16 Time Saved16:18 Costs of treatment 26:44 IMJ paper on resourcing 39:10 Scepticism and stagingProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound ‘RGBA' and ‘Pulse Voyage' by Chill Cole, ‘A Forest Melody' by Tellsonic, ‘Axon Terminal' by Out to the World, ‘Organic Textures 2' by Johannes Bornlof and ‘Fugent' by Lupus Nocte. Image courtesy of Wikimedia Commons and University of Pittsburgh. Editorial feedback kindly provided by physicians of the podcast editorial group Ronaldo Piovezan, Aidan Tan, Hugh Murray, Joseph Lee, Rahul Barmanray, Simeon Wong and Sebastian Lambooy. Thanks also to Profs Bruce Campbell, Mike Parsons and Amy Brodtmann and registrars Jamie Bellinge and Karan Singh for additional insights into research methods. Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

Phase III of The Change Leader's Roadmap: Assess the Situation to Determine Design Requirements enables the upcoming Design work for your project to be handled in the most informative and aligned way possible. In it, you are assessing relevant (four quadrant) aspects of the organization and its culture for what already support your desired future state, what blocks it and what might need to be added brand new. It also considers best practices from other organizations who have made this type of change, and importantly, requests input from your stakeholders and end-users. One unique addition to this phase is the determination of the leaders' boundary conditions for the solution--what are the “givens” or lines in the sand the design scenario must respect. All this helps to align the people doing the design to know what the solution needs to meet to be successful, your Design Requirements.Hosted by Ausha. See ausha.co/privacy-policy for more information.

The Stormwall has finally come down and the 4 SPaRC Jedi Council members have finally been able to escape the Occlusion Zone! Hayley and Brian are joined, as always, by James "Yodahew" Hewings and Todd "Suds" Sedlacek, this time to discuss Phase III of Star Wars: The High Republic, Trials of the Jedi, and also the overarching story of all 3 Phases, and what did and did not work in this massive multimedia endeavor. Plus James regales us with his "Ode To Geode". EMAIL: SPARCPODCAST@GMAIL.COMTWITTER: https://twitter.com/SourcePagesCastINSTAGRAM: https://www.instagram.com/thesourcepagespodcast/FACEBOOK: https://www.facebook.com/SPARCPODCASTSPaRC's Podcast Buddies:Across the Bifrost: The Mighty Thor - https://podcasts.apple.com/us/podcast/across-the-bifrost-the-mighty-thor-podcast/id1572200841Dan and Ian Have Questions - https://podcasts.apple.com/us/podcast/dan-and-ian-have-questions-podcast/id1587402809Commute: The Podcast - https://podcasts.apple.com/us/podcast/commute-the-podcast/id1552657624Segabits - https://segabits.com/Machtails From the Cantina - https://www.facebook.com/machtailsfromthecantina/Rebel Force Radio Presents "The Babu Freaks" - https://www.rebelforceradio.com/shows/category/BaJacked Kirby - https://podcasts.apple.com/us/podcast/jacked-kirby/id1248146026So Weird So Fun - https://podcasts.apple.com/us/podcast/so-weird-so-fun-swsf-friends-through-fandom/id1793135012Star Wars YOU-niverse - https://podcasts.apple.com/us/podcast/star-wars-you-niverse-podcast/id1704904756

Wednesday, September 10, 2025. Week 37. CAMP4 Press Release:  https://www.linkedin.com/posts/caleb-moore-4382704_syngap1-activity-7371545171047628800-zVqR   Let me tell you a story: EW Story, concern over viability of C4. Easy to follow financials, Mrkt Cap and Net assets of ~$40M.  Net income/EBITDA of -$12.6M in Q2.   Running Phase I / II trials and ramping up for Phase III, not cheap.  They need more than they had and capital is hard to get in this market. But here is the good part, the data is solid, the team is strong, and the SYNGAP1 Ecosystem is excited to have a first mover. SRF was thrilled to be invited, not just because we believe in C4, but because we wanted to send a meaningful signal to other investors that we are working closely with C4 and are eager to support their success.  I believe that our investment, while modest, sent that signal and helped this raise become oversubscribed. The board worked hard on this one. Now for hard questions: Are we conflicted? No.  We will transparently share info about all trials for products with good data.  ( See #S10e172 for ASGCT Data https://youtu.be/9xO1TcO1Eus )  Will other companies be upset?  Unlikely.  Stoke and Praxis are the only companies publicly working on SYNGAP1 that are close to this point and they are not worried about financial viability, but if they do want to do a raise for their SYNGAP1 program, they should certainly call us. What will other companies think? Indeed we are de-risking the disease by showing that our kids are modifiable with ASOs which are the majority of the therapies in scope.  This is a huge favor to others looking at this space.   Isn't this taking a risk with our funds?  Depends.  But if it is, it's a risk worth taking.  Remember we are the smallest investor, we only committed up to $1M, so other professional biotech investors put in $99M. What was the process?  C4 came to us, we decided it was worth talking to the board who had multiple discussions but we said yes in less than a week and that was last week. When is the trial? 2H26 Less than a year from now.  With this financing, I am sure of it. As I write this, the $CAMP stock closed up $0.80 or +40%.  Which is solid.  The market is starting to agree with the wise investors and SRF!  Yes we need a cure.  https://www.linkedin.com/posts/curesyngap1_savekramerdavis-activity-7371607032807763968-PVfG   See you Friday: Beacon of Hope September 12, 2025 - Boston, MA cureSYNGAP1.org/Beacon25   SOCIAL MATTERS - 4,311 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  - 1,430 YouTube.  https://www.youtube.com/@CureSYNGAP1    - 11,286 Twitter https://twitter.com/cureSYNGAP1  - 46k Insta https://www.instagram.com/curesyngap1/    Episode 182 of #Syngap10 #CureSYNGAP1 #Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 5, 2025. In this episode: the US MASH market after Wegovy's approval; AstraZeneca and Mineralys in close hypertension race; United Therapeutics' Phase III win in IPF; Corsera aims to predict and prevent cardiovascular disease; and Ionis's RNA-targeted win in severe hypertriglyceridemia. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RKP4E4CFGFGGXBRVXTI73V27U4/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. During a Senate hearing, Robert F. Kennedy Jr. faced criticism for spreading anti-vaccine views and breaking promises regarding vaccines. The FDA released rejection letters for companies like Lykos Therapeutics, Stealth Biotherapeutics, and Regeneron. Ousted CDC director Susan Monarez accused Kennedy of firing her for not supporting Covid-19 recommendations from an advisory panel with "antivaccine rhetoric." Hengrui Pharmaceuticals signed lucrative deals with Merck and GSK, while the FDA promised to release future Complete Response Letters promptly. In other news, Sanofi's anti-OX40 blocker failed in a Phase III study, Gilead partnered with the US State Department for low-income countries, and AC Immune announced workforce cuts. Kennedy was accused of lying during the hearing, and the FDA released a new rare disease approval framework.

Sal talks The High Republic Adventures Phase III comic mini-series!This is my FAVORITE comic series!Daniel José Older and Harvey Tolibao make a perfect comic team!Love lost! Found! and a Wedding Spectacular!!Farzala and Qort lead at the battle of Eriadu!Maz and her pirates! Crash and her crew!Tarkin family business!!Gavi and Driggit at The Battle of Eriadu!The Warden! The Nihil! And even a little Niv Drendow!Memorial to the fallen!Bookended by memories and music ⁠⁠⁠⁠⁠⁠⁠Check out the Rogue Rebels The High Republic playlist!!⁠⁠⁠⁠⁠⁠⁠Check out the Rogue Rebels Star Wars comics playlist!!⁠⁠⁠⁠⁠⁠⁠⁠Follow us EVERYWHERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@TheRogueRebels on Bluesky!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG: @TheRogueRebels ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Rogue Rebels on FB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok @TheRogueRebels

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Regeneron's experimental drug for myasthenia gravis, cemdisiran, has shown promising results in a Phase III trial and the company is aiming to file for FDA approval by 2026. Pharmaceutical spending in China has reached record levels, with more than $48 billion spent in the first half of the year. Former FDA Commissioner Scott Gottlieb has raised concerns about the US losing its edge in biopharma innovation to China. Additionally, a drug program for a rare neurodegenerative disorder has been discontinued by Amylyx, while pharma companies are increasingly focusing on scientific research and partnerships. Lilly's obesity pill is heading to the FDA for approval, AbbVie is investing in psychedelics, and HHS has announced more changes in the industry. The pharmaceutical landscape is rapidly evolving with new developments and challenges arising.Pharma CEOs are facing increasing pressure amid political turmoil and public distrust over drug pricing. The industry spent over $48 billion in China in the first half of the year, with expectations of increased deal volume in the future. Legal experts are working to determine ownership rights of AI creations in biotech. Obesity treatments are being compared for effectiveness, while biotech companies are making strides in AI-driven manufacturing. Job opportunities in gene therapy and biostatistics are available.

Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to head to the FDA with a new drug application. For more in-depth discussion on the oral weight-loss space, check out a special episode of The Weekly. And stay tuned to BioSpace for more unique coverage of this market as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland. On the business side of biopharma, AbbVie turned back to neuropsychiatric therapies this week, acquiring partner Gilgamesh Pharmaceuticals' lead depression candidate for $1.2 billion. The deal is a display of resilience for AbbVie in the neuropsychiatric space as well, after the stunning failure last November of schizophrenia asset emraclidine—picked up in its nearly $9 billion acquisition of Cerevel Therapeutics. And is the cooler late summer weather thawing the IPO market? Neuropsych-focused LB Pharma revealed in an SEC filing on Friday that it plans to take the plunge, ending a six-month stalemate in biotech IPOs.  Finally, the Department of Health and Human Services (HHS) has been busy this past week. On Monday, the CDC named Retsef Levi—a known vaccine critic—to head the agency's COVID-19 immunization working group, just as reports surfaced that the Trump administration could be “within months” of banning the COVID-19 vaccine in the U.S. Meanwhile, the FDA issued new draft guidance for cancer drug developers that prioritizes the use of survival data, and the agency began publishing drug-related adverse event reports daily.   HHS itself has also been the subject of recent headlines, announcing that it will no longer recognize employee unions, and last week, hundreds of HHS staffers penned an open letter calling on Secretary Kennedy to tone down what they called “dangerous and deceitful statements” that have fostered distrust against federal health workers, exposing them to physical harm. This followed the Aug. 8 shooting at CDC headquarters in Atlanta.   Finally, multinational pharmaceutical companies spent more than $48 billion on partnerships with China in the first half of 2025 alone, according to a new report from IQVIA—more than in all of 2024.  

Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month, shares of both Eli Lilly and Viking Therapeutics took a hit as investors reacted negatively to highly anticipated Phase III and Phase II results for their respective candidates.While the 9.1% placebo-adjusted weight loss generated by Lilly's orforglipron over 72 weeks was an efficacy miss by most analyst accounts, tolerability tripped up oral VK2735's otherwise best-case efficacy scenario—10.9% weight loss after just 13 weeks. These murky results have left observers wondering, just how game-changing these pills will be and which ones will be most effective?In such a hot space, Lilly's and Viking's results—which follow Novo Nordisk's new drug application for an oral form of Wegovy in May—are only the tip of the iceberg. Stay tuned to BioSpace for further in-depth coverage of the space as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland.

I remember hearing these amapiano tracks back in 2020 - 2021 tough times but the music kept us going and still is. I'll call this one "night pulse" definitely amapiano that never sleeps.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has received approval for label expansion, potentially boosting its market performance. Tonix has also secured approval for a new fibromyalgia medication. Additionally, Novo has teamed up with GoodRx to provide lower prices for its drugs. Merck KGaA has made a significant investment of $2 billion in RNA-targeting technology through a collaboration with Skyhawk Therapeutics. On the sterilization front, Fedegari now offers tailored solutions for the pharmaceutical sector. In other updates, Pfizer's sickle cell therapy did not succeed in Phase III trials, while gene therapy company Kriya has raised an impressive $313 million. Kennedy has shown support for mRNA vaccines in cancer treatment. Bausch Health has closed a facility, Precigen has received FDA approval for an immunotherapy drug, and Eli Lilly has partnered with Superluminal in the obesity pipeline. Stay tuned for more industry news and developments.

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 15, 2025. In this episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-365OXHOS2RFXHPEDQIURY6LFDI/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

What if we could finally crack the code on treating brain cancer by opening the door that's blocked 98% of therapies? In this episode, Dr. Michael Canney, Chief Scientific Officer of Carthera, reveals how SonoCloud—a revolutionary ultrasound implant—temporarily opens the blood-brain barrier to deliver chemotherapy directly to tumors like glioblastoma. With over 100 patients enrolled in a Phase III trial across 40 global sites, this isn't just a bold idea—it's happening now. Michael also shares real-world lessons in scaling trials, FDA navigation, and aligning science with commercial success. If you're passionate about disruptive innovation in neuro-oncology, you'll want to hear how Carthera is changing the game.

Vinay Prasad is back at the FDA as chief of the FDA's Center for Biologics Evaluation and Research. Prasad's return—which hit the news wires Saturday morning—came just 10 days after his unexpected exit on July 29, following blowback over the saga involving Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, and a campaign by conversative personalities to oust the outspoken physician.Elsewhere in the government, Gray Delany, former head of HHS' and President Donald Trump's Make America Healthy Again agenda, has been fired—days after Health and Human Services Secretary Robert F. Kennedy Jr. axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority. Delany's ouster came after he allegedly butted heads with other agency officials over how announcements were made, according to reporting from Endpoints News. The mRNA contract cuts, meanwhile, have sparked criticism from the scientific community and concern that the growing anti-mRNA sentiment could also have a negative effect on research for cancer therapeutics.In somewhat related news, the Annals of Internal Medicine is refusing to retract a large-scale study it ran in July that pointed to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions, despite Kennedy's criticism. In an op-ed published earlier this month, the Health Secretary took issue with the study's design.In obesity news, biopharma darling Eli Lilly suffered a rare chink in its normally impenetrable GLP-1 armor. The first Phase III trial for oral weight loss therapy orforglipron read out last week, and the results were underwhelming, at least to Wall Street. Truist Securities wrote that the data support approval but “leaves room for competition.” This is good news for a whole host of companies, including Roche, Viking, Terns and Rhythm Pharmaceuticals, who all have weight loss pills at various stages of development.And in gene therapy, the hits just keep coming. The FDA has limited the use of bluebird bio's gene therapy Skysona to patients with cerebral adrenoleukodystrophy for whom no other therapies or stem cell donors are available, due to a heightened risk of blood cancers. This follows safety issues in gene therapy trials experienced by Allogene, and, of course, Sarepta Therapeutics. This week in ClinicaSpace, Dan Samorodnitsky explored the future of AAV technology. And in BioPharm Executive, Annalee Armstrong sat down with Chris Anzalone, CEO of Arrowhead Pharmaceuticals—Sarepta's key strategic partner—to learn how his company has been weathering the storm.

Phase III data from Lilly's orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why the first-in-class oral small molecule GLP-1R agonist's clean safety profile and clear manufacturing advantage over oral peptides give the product a leg-up in the market.They then discuss Vinay Prasad's return to FDA after a brief hiatus, the revamped strategy of 32-year-old San Diego biotech Acadia Pharmaceuticals, and an attempt in the Senate to revive the Biosecure Act targeting China biotechs.Finally, the analysts preview this year's Back to School package, which reimagines FDA. At a time of unprecedented change in government agencies, BioCentury's 33rd Back to School asks what FDA could look like if it were reorganized from the ground up to create the regulator patients deserve and industry needs. View full story: https://www.biocentury.com/article/656727#orforglipron #CBER #VinayPrasad #AcadiaPharmaceuticals00:00 - Introduction00:49 - Prasad07:09 - Back to School12:29 - Lilly Obesity21:58 - Acadia's Comeback28:50 - Biosecure ActTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode of the Exploring Mining Podcast, we dive deep into the exciting journey of Terra Balcanica Resources Corp., a polymetallic and energy explorer making waves in the mining industry. Alex Mišković, P.Geo. and CEO, shares the company's evolution from a private venture started in 2020 to a publicly listed entity on the CSE (TERA) in 2022, raising over $9.5 million to fuel its ambitious exploration programs including advanced geophysics, soil sampling, and diamond drilling . Alex highlights the strategic importance of antimony, a critical metal for Europe's defense and energy transition sectors, and Silver, a cornerstone of the project, continues to deliver intercepts that rival global leaders, With a strategic foothold in Bosnia and Herzegovina's mining-friendly jurisdiction, Terra is capitalizing Phase III drilling campaign, silver-antimony intercepts, and more!About the CompanyTerra Balcanica is a polymetallic and energy metals exploration company targeting large-scale mineral systems in the Balkans of southeastern Europe and northern Saskatchewan, Canada. The Company has 90% interest in the Viogor-Zanik Project in eastern Bosnia and Herzegovina. The Canadian assets comprise a 100% optioned portfolio of uranium-prospective licences at the outskirts of the world-renowned Athabasca basin: Charlot-Neely Lake, Fontaine Lake, Snowbird, and South Pendleton. The Company emphasizes responsible engagement with local communities and stakeholders. It is committed to proactively implementing Good International Industry Practice (GIIP) and sustainable health, safety, and environmental management. https://terrabresources.com/en/ Follow on X @terrabalcanicaDisclaimer/Disclosure: This podcast featuring are paid for content at Investorideas.com, (payment disclosure). Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.aspFollow us on X @investorideas @Exploringmining Follow us on Facebook https://www.facebook.com/Investorideas #CommodityInvesting #MiningStocks #SilverMining #PreciousMetals #SilverPrice #ExplorationStocks #InvestInSilver #MiningInvestments #Antimony #ResourceStocks

Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vinay Prasad's abrupt departure hours after the recording of last week's episode of The Weekly. While the situation is being billed as temporary, rumors are swirling that structural changes may be afoot at the FDA with Commissioner Marty Makary looking for better drug, biologic alignment.Meanwhile, the agency has come under criticism for another recent decision—one apparently driven by CDER's Oncology Center of Excellence director Richard Pazdur: the rejection of Replimmune's advanced melanoma drug, RP1. According to reporting by multiple outlets, Pazdur opposed the consensus opinion of CBER staff to approve the drug. The research team behind Replimmune's Phase III study penned an open letter to the FDA on Friday responding to the issues outlined in the agency's complete response letter. Meanwhile, the FDA's Sarepta saga continues, highlighting “unprecedented” FDA leaks and a veritable communications disaster.On the business side of biopharma, Q2 earnings continue to unfurl, with Pfizer, Vertex, BioNTech, Merck and Moderna all reporting this past week. Merck's $3 billion savings push has claimed 6,000 jobs, contributing to a brutal July that saw the entire biopharma industry axe 7,900 employees, a 487% year-over-year increase, based on BioSpace tallies. Meanwhile, Pfizer CEO Albert Bourla confirmed he has been in direct contact with President Donald Trump to negotiate a path forward on Most Favored Nation drug pricing after the president sent letters to 17 Big Pharma companies—and posted on his Truth Social platform—asking them to comply with the policy within 60 days or face potential unspecified consequences.In other policy news, the Centers for Medicare and Medicaid Services is reportedly considering coverage of GLP-1 drugs for weight management and obesity—reviving a Biden era proposal the Trump admin scrapped earlier this year.Finally, in BioPharm Executive this week, we have a special report on the situation in China as international drugmakers swoop into the region to find new drug candidates, while other companies build their therapeutic farm systems from incubators and venture arms. And check out BioSpace's brand new Manufacturing Brief, where we bring you the latest news and analysis in the area of biopharma manufacturing, starting with a feature on how to make cell and gene therapies commercially viable.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Julie's brand new Big Gorgeous Goals: Official Workbook can be ordered now! Grab your copy.Dr. Joan Fallon shares her journey from clinical practice to founding Curemark, a biotech company developing novel therapies for Autism based on her discovery of enzyme deficiencies in children with the condition. Her innovative approach challenges traditional pharmaceutical development by addressing the physiological root causes of Autism rather than just treating symptoms.Dr. Joan Fallon, Founder and CEO of Curemark, is a visionary scientist dedicated to improving the health and well-being of children globally. Under her leadership, Curemark has developed novel therapies for diseases with limited treatment options, including a Phase III clinical program for Autism and research on Parkinson's Disease, schizophrenia, and addiction. The company's first drug, CM-AT, targeting autism, has earned Fast Track status from the FDA. Dr. Fallon holds over 400 patents, has authored numerous scholarly articles, and is a sought-after lecturer. Recognized as one of Goldman Sachs' Top 100 Most Intriguing Entrepreneurs of 2020 and a recipient of the EY Entrepreneur Of The Year Award in 2017, she also published her first book, Goodbye, Status Quo: Reimagining the Landscape of Innovation, in 2022. A respected business leader, doctor, and academic, Joan is passionate about sharing her insights on entrepreneurship and innovation.You can connect with Dr. Joan Fallon on LinkedIn. You can also learn more about Curemark on their website.Love the show or want to request a topic? Send us a text! (All submissions are anonymous, so if you'd like a reply, please include your email address!)You can connect with Julie on LinkedIn or Instagram. Find Julie's writing at her blog or by ordering her book Big Gorgeous Goals and the brand new official companion workbook! What did you think of this conversation? We'd love if you'd rate or review our show!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The U.S. Department of Health and Human Services (HHS) has begun formally laying off thousands of employees following a Supreme Court ruling allowing the Trump administration to reorganize the agency. FDA Commissioner Marty Makary has proposed lowering industry user fees to make it easier for smaller companies and academics to participate in the regulatory process. Developments in HIV and prep treatments are being presented at the IAS 2025 conference, while a new dual glp-1/gip molecule from Hengrui and Kailera Therapeutics has shown promising weight loss results in Phase III trials. A new 96-channel pipettor from Rainin is also being promoted to streamline library preparation for next-generation sequencing. Updates on Acadia's pipeline, FDA rejections for Ultragenyx, advancements in narcolepsy treatments by Takeda, and the potential use of psychedelics in depression treatment are also discussed in this episode. Stay tuned for more updates on the latest news and developments in the pharmaceutical and healthcare industries.

Oz joins Jose and Trev to try and untangle some of the confusion around phase III

The FDA's Diversity Action Plan guidance underwent several changes in recent months—with the draft guidance taken down, restored, and then pulled again—creating uncertainty for sponsors planning Phase III and pivotal trials across all therapeutic areas. With the final guidance expected by June 26, CRO regulatory leaders reflected on how companies can manage this evolving environment. They explored: The impact of the FDA's changing Diversity Action Plan guidance on sponsors' trial planning How companies adapted strategies to maintain inclusivity goals amid shifting regulatory priorities Broader implications for trial design, pipeline strategies, and sponsor approaches in the global drug development landscape This episode is part 2 of 4 in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Stay tuned for the next episode, where we'll continue exploring the key forces shaping the future of clinical trials. Listen to part 1 here: https://insights.citeline.com/scrip/partnered-content/podcast-series-navigating-regulatory-changes-market-dynamics-cro-perspectives-on-the-future-of-clinical-trials-26Q4Q35N6BHTZGLHIKHK6V2NXY/

Sal talks The High Republic comic mini-series' Echoes of Fear and Dispatches From the Occlusion Zone!The High Republic is almost over!!Old Pathfinder EX droids sending messages!Things are building on Eriadu!Driggit hacking droids and sending messages!Emerick Caphtor and Niv Drendow... best friends?Ty Yorick heads to Dalna!Tay and Lourna fighting side by side!Storytime with Reath Silas!Sith Lord Darth Ravi and the puzzle moon!More stories of Barnabus Vim!Legends of the Rod of Ages and the last Echo Stone! ⁠⁠⁠⁠⁠Check out the Rogue Rebels The HighRepublic playlist!!⁠⁠⁠⁠⁠Follow us EVERYWHERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠@TheRogueRebels on Bluesky!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠IG: @TheRogueRebels ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Rogue Rebels on FB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok @TheRogueRebels

Topics covered in this episode: * Free-threaded Python no longer “experimental” as of Python 3.14* typed-ffmpeg pyleak * Optimizing Test Execution: Running live_server Tests Last with pytest* Extras Joke Watch on YouTube About the show Sponsored by PropelAuth: pythonbytes.fm/propelauth66 Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Free-threaded Python no longer “experimental” as of Python 3.14 “PEP 779 ("Criteria for supported status for free-threaded Python") has been accepted, which means free-threaded Python is now a supported build!” - Hugo van Kemenade PEP 779 – Criteria for supported status for free-threaded Python As noted in the discussion of PEP 779, “The Steering Council (SC) approves PEP 779, with the effect of removing the “experimental” tag from the free-threaded build of Python 3.14.” We are in Phase II then. “We are confident that the project is on the right path, and we appreciate the continued dedication from everyone working to make free-threading ready for broader adoption across the Python community.” “Keep in mind that any decision to transition to Phase III, with free-threading as the default or sole build of Python is still undecided, and dependent on many factors both within CPython itself and the community. We leave that decision for the future.” How long will all this take? According to Thomas Wouters, a few years, at least: “In other words: it'll be a few years at least. It can't happen before 3.16 (because we won't have Stable ABI support until 15) and may well take longer.” Michael #2: typed-ffmpeg typed-ffmpeg offers a modern, Pythonic interface to FFmpeg, providing extensive support for complex filters with detailed typing and documentation. Inspired by ffmpeg-python, this package enhances functionality by addressing common limitations, such as lack of IDE integration and comprehensive typing, while also introducing new features like JSON serialization of filter graphs and automatic FFmpeg validation. Features : Zero Dependencies: Built purely with the Python standard library, ensuring maximum compatibility and security. User-Friendly: Simplifies the construction of filter graphs with an intuitive Pythonic interface. Comprehensive FFmpeg Filter Support: Out-of-the-box support for most FFmpeg filters, with IDE auto-completion. Integrated Documentation: In-line docstrings provide immediate reference for filter usage, reducing the need to consult external documentation. Robust Typing: Offers static and dynamic type checking, enhancing code reliability and development experience. Filter Graph Serialization: Enables saving and reloading of filter graphs in JSON format for ease of use and repeatability. Graph Visualization: Leverages graphviz for visual representation, aiding in understanding and debugging. Validation and Auto-correction: Assists in identifying and fixing errors within filter graphs. Input and Output Options Support: Provide a more comprehensive interface for input and output options, including support for additional codecs and formats. Partial Evaluation: Enhance the flexibility of filter graphs by enabling partial evaluation, allowing for modular construction and reuse. Media File Analysis: Built-in support for analyzing media files using FFmpeg's ffprobe utility, providing detailed metadata extraction with both dictionary and dataclass interfaces. Michael #3: pyleak Detect leaked asyncio tasks, threads, and event loop blocking with stack trace in Python. Inspired by goleak. Use as context managers or function dectorators When using no_task_leaks, you get detailed stack trace information showing exactly where leaked tasks are executing and where they were created. Even has great examples and a pytest plugin. Brian #4: Optimizing Test Execution: Running live_server Tests Last with pytest Tim Kamanin “When working with Django applications, it's common to have a mix of fast unit tests and slower end-to-end (E2E) tests that use pytest's live_server fixture and browser automation tools like Playwright or Selenium. ” Tim is running E2E tests last for Faster feedback from quick tests To not tie up resources early in the test suite. He did this with custom “e2e” marker Implementing a pytest_collection_modifyitems hook function to look for tests using the live_server fixture, and for them automatically add the e2e marker to those tests move those tests to the end The reason for the marker is to be able to Just run e2e tests with -m e2e Avoid running them sometimes with -m "not e2e" Cool small writeup. The technique works for any system that has some tests that are slower or resource bound based on a particular fixture or set of fixtures. Extras Brian: Is Free-Threading Our Only Option? - Interesting discussion started by Eric Snow and recommended by John Hagen Free-threaded Python on GitHub Actions - How to add FT tests to your projects, by Hugo van Kemenade Michael: New course! LLM Building Blocks in Python Talk Python Deep Dives Complete: 600K Words of Talk Python Insights .folders on Linux Write up on XDG for Python devs. They keep pulling me back - ChatGPT Pro with o3-pro Python Bytes is the #1 Python news podcast and #17 of all tech news podcasts. Python 3.13.4, 3.12.11, 3.11.13, 3.10.18 and 3.9.23 are now available Python 3.13.5 is now available! Joke: Naming is hard

The Pittsburgh Steelers started Phase III of their Organized Team Activities (OTAs) Tuesday, and while some might overlook these workouts because their in shorts, there is still a lot of value in these workouts. These workouts might not be an indicator of teams which will win more games in 2025, but they certainly aren't meaningless. That's the topic of the Wednesday "Let's Ride" podcast with Jeff Hartman, as well as the Mailbag Segment. This podcast is a part of the Steel Curtain Network, a part of the Fans First Sports Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

Paul Kuharsky of Paul Kuharsky dot com joins the show to talk all things Titans and NFL as they open up Phase III of OTAs.  What storylines are we paying attention to?  How will the backup QB situation play out?  Is there still a place for Treylon Burks on the team?  We take your phones for PK.

The Jaguars are about to be at the halfway point of OTA's / Phase III of the Offseason Program. What have we learned? What questions do we still have?1010XL Jaguars Beat Reporter Hays Carlyon joins Mia O'Brien as he does each Wednesday to discuss + answer your questions LIVE!0:00 Open0:10 Intro ... it's Hot in Jax4:15 Travis Etienne & State of Running Back Room7:40 Bhayshul Tuten, specifically12:50 Weight Loss of Key Defensive Veterans18:40 "Getting Home with Four" & LB Play23:10 Curious Case of Devin Lloyd26:45 Trevor Lawrence: Good or Bad?35:04 Dyami Brown's Impact37:57 Which players will benefit most from coaching?42:20 Epic Hays Carlyon rant!Mia O'Brien is joined live by a rotation of guests Monday's, Wednesday's and Friday's at 9:04 AM. Episodes are also available on-demand at the 1010XL Podcast Network wherever you get your podcasts.

Cam Ward took the field against a defense for the first time as a Titan during Phase III of OTAs, and he was...fine. Is that a good thing? 

The Titans are hitting the field today for Phase III of OTAs.  There is one national pundit who is giving the Titans some love.  What are we looking for at OTAs, and we get Joe's thoughts on the team trying to build leadership this offseason.  We get into some of the latest news and notes from the SEC spring meetings and what that could mean for the CFP.  We finish up the hour with the Rex Rant.

Faraday Copper says they have made a new blind discovery of the Winchester Breccia during their Phase III drill program at the Copper Creek Project in Arizona. New exploration results from Outcrop Silver & Gold and Soma Gold. Kenorland Minerals has wrapped up its winter drill program with Auranova at the South Uchi Project. This episode of Mining Stock Daily is brought to you by... Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Calibre Mining is a Canadian-listed, Americas focused, growing mid-tier gold producer with a strong pipeline of development and exploration opportunities across Newfoundland & Labrador in Canada, Nevada and Washington in the USA, and Nicaragua. With a strong balance sheet, a proven management team, strong operating cash flow, accretive development projects and district-scale exploration opportunities Calibre will unlock significant value.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.calibremining.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Kenyan President William Ruto wrapped up a four-day visit to China on Friday and returned home with a massive new railway deal and more than a billion dollars of investment pledges. Ruto's successful closing of the Phase III extension of the Standard Gauge Railway to the Ugandan border comes after nearly a decade of Kenyan lobbying in China. Also, this week, Eric & Géraud are at the Salzburg Global Forum in Austria, where they joined a diverse group of civil society stakeholders from across Africa to participate in a lively week-long conference on centering an African vision for a new multilateral future. JOIN THE DISCUSSION: X: @ChinaGSProject | @christiangeraud Facebook: www.facebook.com/ChinaAfricaProject YouTube: www.youtube.com/@ChinaGlobalSouth Now on Bluesky! Follow CGSP at @chinagsproject.bsky.social FOLLOW CGSP IN FRENCH AND ARABIC: Français: www.projetafriquechine.com | @AfrikChine Arabic: عربي: www.alsin-alsharqalawsat.com | @SinSharqAwsat JOIN US ON PATREON! Become a CGSP Patreon member and get all sorts of cool stuff, including our Week in Review report, an invitation to join monthly Zoom calls with Eric & Cobus, and even an awesome new CGSP Podcast mug! www.patreon.com/chinaglobalsouth

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture Trump has now ended the attack on gas stoves, everything that Biden has done is being reversed. Lee Zeldin found the money and is returning to the people. Politico admits the job numbers are fake. Trump has begun the parallel economy, tariffs are being implemented. The end of the Fed is coming. The [DS] players are panicking, the people are now seeing that there are rats everywhere. DOGE is setting up a transparent system so the people can see it all. This was not just another 4 year election this was a crossroads to see if can keep the country. Phase I and II happening right now. Once the people see the criminals and the treason that they have committed we will be moving to Phase III, a traitors justice.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Trump Admin Formally Ends Biden's War on Gas Stoves The Consumer Product Safety Commission is formally ending a review that it initiated during the Biden administration to assess the potential health risks posed by gas-powered stovetops. In a statement to the Washington Free Beacon, Consumer Product Safety Commission acting chairman Peter Feldman said he considers the matter "concluded" and emphasized that the federal government should not interfere with consumer choice. Feldman's comments effectively put an end to a years-long process that critics feared would lead to a broad ban on gas stoves. " "I became Acting Chairman of the United States Consumer Product Safety Commission in January 2025, shortly after President Trump's inauguration," he continued. "So long as I have a say in the matter, the CPSC is out of the gas-stoves-banning business. The agency has no plans to advance such a rule." Source: freebeacon.com EPA Chief Lee Zeldin Pledges to Recover $20 Billion Lost by Biden Administration for Climate Projects Lee Zeldin, EPA Chief for the Trump administration, has pledged to recover the $20 billion in taxpayer funds lost by the Biden administration to climate projects. Zeldin made the announcement in a video posted to social media on Wednesay when he charged the Biden administration of “throwing gold bars of the Titanic” in relation to the money lost on climate projects that he said was a “rush job with reduced oversight.” “The days of irresponsibly shoveling boatloads of cash to far-left activist groups in the name of environmental justice and climate equity are over,” Zeldin said. “The American public deserves a more transparent and accountable government than what transpired these past four years.” Source: breitbart.com https://twitter.com/epaleezeldin/status/1889840040622321778 Rep. Jan Schakowsky Suggests Women Might Not Pursue Jobs in Manufacturing Because “Man” is in the Name (Video) Rep. Jan Schakowsky (D-IL) pushed a bizarre explanation for why women might not pursue jobs in manufacturing. Schakowsky made her remarks on Wednesday during a Commerce, Manufacturing and Trade subcommittee hearing entitled “AI in Manufacturing: Securing American Leadership in Manufacturing and the Next Generation of Technologies.” Schakowsky suggested that perhaps the reason fewer women choose a career in manufacturing is that the term has the word “man” in it. https://twitter.com/libsoftiktok/status/1889833714974416938?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1889833714974416938%7Ctwgr%5E405aa74609e691f5897438e7cd78045186bc95f1%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2025%2F02%2Frep-jan-schakowsky-suggests-women-might-not-pursue%2F Source: thegatewaypunidt.com